Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1954 1
1956 1
1967 1
1982 2
1984 1
1985 3
1986 1
1987 1
1989 3
1990 4
1991 2
1994 1
1995 1
1996 1
1998 1
2000 3
2001 1
2004 1
2008 1
2009 1
2015 2
2019 1
2020 1
2021 3
2022 1
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Results by year

Filters applied: . Clear all
Page 1
AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.
Fok JHL, Ramos-Montoya A, Vazquez-Chantada M, Wijnhoven PWG, Follia V, James N, Farrington PM, Karmokar A, Willis SE, Cairns J, Nikkilä J, Beattie D, Lamont GM, Finlay MRV, Wilson J, Smith A, O'Connor LO, Ling S, Fawell SE, O'Connor MJ, Hollingsworth SJ, Dean E, Goldberg FW, Davies BR, Cadogan EB. Fok JHL, et al. Among authors: willis se. Nat Commun. 2019 Nov 7;10(1):5065. doi: 10.1038/s41467-019-12836-9. Nat Commun. 2019. PMID: 31699977 Free PMC article.
Chancroid.
Willis SE. Willis SE. Prim Care. 1990 Mar;17(1):145-52. Prim Care. 1990. PMID: 2181505 Review.
Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation.
Dillon MT, Guevara J, Mohammed K, Patin EC, Smith SA, Dean E, Jones GN, Willis SE, Petrone M, Silva C, Thway K, Bunce C, Roxanis I, Nenclares P, Wilkins A, McLaughlin M, Jayme-Laiche A, Benafif S, Nintos G, Kwatra V, Grove L, Mansfield D, Proszek P, Martin P, Moore L, Swales KE, Banerji U, Saunders MP, Spicer J, Forster MD, Harrington KJ. Dillon MT, et al. Among authors: willis se. J Clin Invest. 2024 Jan 16;134(2):e175369. doi: 10.1172/JCI175369. J Clin Invest. 2024. PMID: 37934611 Free PMC article. Clinical Trial.
Prevalence and predictors of urine culture contamination in primary care: A cross-sectional study.
Hansen MA, Valentine-King M, Zoorob R, Schlueter M, Matas JL, Willis SE, Danek LCK, Muldrew KL, Zare M, Hudson F, Atmar RL, Chou A, Trautner BW, Grigoryan L. Hansen MA, et al. Among authors: willis se. Int J Nurs Stud. 2022 Oct;134:104325. doi: 10.1016/j.ijnurstu.2022.104325. Epub 2022 Jul 11. Int J Nurs Stud. 2022. PMID: 35914376 Free PMC article. Review.
Epitope Lability of Phosphorylated Biomarkers of the DNA Damage Response Pathway Results in Increased Vulnerability to Effects of Delayed or Incomplete Formalin Fixation.
Wiseman EJ, Moss JI, Atkinson J, Baakza H, Hayes E, Willis SE, Waring PM, Rodriguez Canales J, Jones GN. Wiseman EJ, et al. Among authors: willis se. J Histochem Cytochem. 2023 May;71(5):237-257. doi: 10.1369/00221554231174069. Epub 2023 Apr 29. J Histochem Cytochem. 2023. PMID: 37119278
Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response.
Willis SE, Winkler C, Roudier MP, Baird T, Marco-Casanova P, Jones EV, Rowe P, Rodriguez-Canales J, Angell HK, Ng FSL, Waring PM, Hodgson D, Ledermann JA, Weberpals JI, Dean E, Harrington EA, Barrett JC, Pierce AJ, Leo E, Jones GN. Willis SE, et al. Br J Cancer. 2021 Dec;125(12):1666-1676. doi: 10.1038/s41416-021-01560-1. Epub 2021 Oct 18. Br J Cancer. 2021. PMID: 34663950 Free PMC article.
Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity.
Sacco A, Federico C, Todoerti K, Ziccheddu B, Palermo V, Giacomini A, Ravelli C, Maccarinelli F, Bianchi G, Belotti A, Ribolla R, Favasuli V, Revenko AS, Macleod AR, Willis B, Cai H, Hauser J, Rooney C, Willis SE, Martin PL, Staniszewska A, Ambrose H, Hanson L, Cattaneo C, Tucci A, Rossi G, Ronca R, Neri A, Mitola S, Bolli N, Presta M, Moschetta M, Ross S, Roccaro AM. Sacco A, et al. Among authors: willis se. Blood. 2021 Nov 4;138(18):1705-1720. doi: 10.1182/blood.2020010572. Blood. 2021. PMID: 34077955 Free PMC article.
Determining a urinary-specific antibiogram and risk factors of trimethoprim/sulfamethoxazole, ciprofloxacin and multidrug resistance among Enterobacterales in primary care.
Valentine-King M, Hansen MA, Zoorob R, Schlueter M, Matas JL, Willis SE, Danek LCK, Muldrew K, Zare M, Hudson F, Atmar RL, Chou A, Trautner BW, Grigoryan L. Valentine-King M, et al. Among authors: willis se. J Antimicrob Chemother. 2024 Mar 1;79(3):559-563. doi: 10.1093/jac/dkae004. J Antimicrob Chemother. 2024. PMID: 38217846
Reversible cardiomyopathy due to selenium deficiency.
Reeves WC, Marcuard SP, Willis SE, Movahed A. Reeves WC, et al. Among authors: willis se. JPEN J Parenter Enteral Nutr. 1989 Nov-Dec;13(6):663-5. doi: 10.1177/0148607189013006663. JPEN J Parenter Enteral Nutr. 1989. PMID: 2614867
AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib.
Flemington V, Davies EJ, Robinson D, Sandin LC, Delpuech O, Zhang P, Hanson L, Farrington P, Bell S, Falenta K, Gibbons FD, Lindsay N, Smith A, Wilson J, Roberts K, Tonge M, Hopcroft P, Willis SE, Roudier MP, Rooney C, Coker EA, Jaaks P, Garnett MJ, Fawell SE, Jones CD, Ward RA, Simpson I, Cosulich SC, Pease JE, Smith PD. Flemington V, et al. Among authors: willis se. Mol Cancer Ther. 2021 Feb;20(2):238-249. doi: 10.1158/1535-7163.MCT-20-0002. Epub 2020 Dec 3. Mol Cancer Ther. 2021. PMID: 33273059
42 results